Literature DB >> 19151745

Inhibitory effects of tetrandrine on the Na(+) channel of human atrial fibrillation myocardium.

Li Chen1, Qi-Yong Li, Yan Yang, Zhong-Wen Li, Xiao-Rong Zeng.   

Abstract

AIM: Tetrandrine (Tet) is a Ca(2+) channel blocker and has antiarrhythmic effects. Less information exists with regard to the mechanisms underlying its antiarrhythmic action other than blocking Ca(2+) channels. In this study, the effects of Tet on the Na(+) current (I(Na)) in the atrial myocardium of patients in atrial fibrillation (AF) and sinus rhythm (SR) were investigated, and the characteristics of the Na(+) current were synchronously compared between the AF and SR patients.
METHODS: Na(+) currents were recorded using the whole-cell patch clamp technique in single atrial myocyte of the AF and the normal SR groups. The effects of Tet (40-120 micromol/L) on the Na(+) current in the two groups were then observed.
RESULTS: Tet (60-120 micromol/L) decreased I(Na) density in a concentration-dependent manner and made the voltage-dependent activation curve shift to more positive voltages in the SR and AF groups. After exposure to Tet, the voltage-dependent inactivation curve of I(Na) was shifted to more negative voltages in the two groups. Tet delayed the time-dependent recovery of I(Na) in a concentration dependent manner in both AF and SR cells; however, there were no differences in the effects of Tet on I(Na) density and properties in the two groups. The I(Na) density of AF patients did not differ from that of the SR patients.
CONCLUSION: Tet can block sodium channels with slow recovery kinetics, which may explain the mechanisms underlying the antiarrhythmic action of Tet. The decreased conduction velocity (CV) in AF patients is not caused by the Na(+) current.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151745      PMCID: PMC4002466          DOI: 10.1038/aps.2008.23

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart.

Authors:  R Mandapati; A Skanes; J Chen; O Berenfeld; J Jalife
Journal:  Circulation       Date:  2000-01-18       Impact factor: 29.690

2.  Ionic mechanisms of electrical remodeling in human atrial fibrillation.

Authors:  R F Bosch; X Zeng; J B Grammer; K Popovic; C Mewis; V Kühlkamp
Journal:  Cardiovasc Res       Date:  1999-10       Impact factor: 10.787

3.  Evidence for multiple mechanisms in human ventricular fibrillation.

Authors:  Martyn P Nash; Ayman Mourad; Richard H Clayton; Peter M Sutton; Chris P Bradley; Martin Hayward; David J Paterson; Peter Taggart
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

4.  [The clinical cardiac electrophysiologic effects of tetrandrine].

Authors:  W H Li
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  1993-08

5.  Tetrandrine ameliorates ischaemia-reperfusion injury of rat myocardium through inhibition of neutrophil priming and activation.

Authors:  Y C Shen; C F Chen; Y J Sung
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

6.  Tetrandrine inhibits both T and L calcium channel currents in ventricular cells.

Authors:  Q Y Liu; E Karpinski; P K Pang
Journal:  J Cardiovasc Pharmacol       Date:  1992-10       Impact factor: 3.105

Review 7.  Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies.

Authors:  Stanley Nattel; James Kneller; Renqiang Zou; L Joshua Leon
Journal:  J Cardiovasc Electrophysiol       Date:  2003-10

8.  Atrial distribution of connexin 40 and 43 in patients with intermittent, persistent, and postoperative atrial fibrillation.

Authors:  Matthias Wilhelm; Wolfgang Kirste; Simone Kuly; Kerstin Amann; Winfried Neuhuber; Michael Weyand; Werner Günther Daniel; Christoph Garlichs
Journal:  Heart Lung Circ       Date:  2005-08-25       Impact factor: 2.975

9.  Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm.

Authors:  Tomoko Nao; Tomoko Ohkusa; Yuji Hisamatsu; Noriko Inoue; Tomo Matsumoto; Jutaro Yamada; Akihiko Shimizu; Yasuhiro Yoshiga; Toshihiko Yamagata; Shigeki Kobayashi; Masafumi Yano; Kimikazu Hamano; Masunori Matsuzaki
Journal:  Am J Cardiol       Date:  2003-03-15       Impact factor: 2.778

10.  Effects of tetrandrine on calcium and potassium currents in isolated rat hepatocytes.

Authors:  Hong-Yi Zhou; Fang Wang; Lan Cheng; Li-Ying Fu; Ji Zhou; Wei-Xing Yao
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more
  5 in total

1.  Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

Authors:  T Ohyama; K Sato; K Kishimoto; Y Yamazaki; N Horiguchi; T Ichikawa; S Kakizaki; H Takagi; T Izumi; M Mori
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  In Vitro Study of the Metabolic Characteristics of Eight Isoquinoline Alkaloids from Natural Plants in Rat Gut Microbiota.

Authors:  Chi-Yu He; Jie Fu; Jia-Wen Shou; Zhen-Xiong Zhao; Long Ren; Yan Wang; Jian-Dong Jiang
Journal:  Molecules       Date:  2017-06-04       Impact factor: 4.411

Review 3.  Research Progress on Natural Products' Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels.

Authors:  Jinshan He; Sicong Li; Yumeng Ding; Yujia Tong; Xuebin Li
Journal:  Cardiovasc Ther       Date:  2022-03-22       Impact factor: 3.023

4.  Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation.

Authors:  Xuewen Wang; Guangping Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jan-Mar       Impact factor: 1.636

Review 5.  A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji).

Authors:  Yueping Jiang; Min Liu; Haitao Liu; Shao Liu
Journal:  Phytochem Rev       Date:  2020-04-24       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.